PT - JOURNAL ARTICLE AU - Patrick Heuveline AU - Michael Tzen TI - Three CoViD-19 Mortality Indicators for Temporal and International Comparisons AID - 10.1101/2020.04.29.20085506 DP - 2020 Jan 01 TA - medRxiv PG - 2020.04.29.20085506 4099 - http://medrxiv.org/content/early/2020/05/05/2020.04.29.20085506.short 4100 - http://medrxiv.org/content/early/2020/05/05/2020.04.29.20085506.full AB - In response to the novel coronavirus disease 2019 (CoViD-19) pandemic, national and local institutions have issued public-health orders to slow the spread of the disease. Comparing CoViD-19 trends over time and place may thus provide important public health insights about the impact of different strategies. To aid these comparisons, we illustrate the properties of 3 comparative indicators of CoViD-19 mortality using estimates and projections for the world’s most affected areas. We first demonstrate how a Crude CoViD-19 Death Rate (CCDR) incorporates the temporal dimension of CoViD-19 mortality. We also show how the advantage of the indirectly age-standardized Comparative CoViD-19 Mortality Ratio (CCMR). Finally, we calculate declines in life expectancy at birth that translate CoViD-19 mortality projections into an easily interpretable metric. Projections used to illustrate this yields a .3 of a year decline in life expectancy at birth for the U.S.A., for instance, which would be comparable to the decline in life expectancy at birth between 1992 and 1993 (AIDS mortality) and between 2014 and 2017 (opioid-overdose mortality). Data about the pandemic are changing too rapidly to draw any conclusion from the current values of the indicators, however, and there are multiple reasons to expect upward revisions of these projections.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe authors benefited from facilities and resources provided by the California Center for Population Research at UCLA (CCPR), which receives core support (P2C-HD041022) from the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD).Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data are available online and can be accessed directly or through a web scraping routine that we provide at https://github.com/statsccpr/ind-cov-mort https://www.arcgis.com/apps/opsdashboard/index.html#/bda7594740fd40299423467b48e9ecf6 https://covid19.healthdata.org/ https://www.cdc.gov/nchs/nvss/vsrr/COVID19/index.htm